<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241019100901
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241019100901" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 19 Oct 2024 14:09:02 +0000</lastbuilddate>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Subgroup effects of ticagrelor monotherapy for acute coronary syndrome using individual patient data from the TICO and T-PASS trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39422377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 18:ehae685. doi: 10.1093/eurheartj/ehae685. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39422377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39422377</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae685>10.1093/eurheartj/ehae685</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39422377</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yong-Joon Lee</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Subgroup effects of ticagrelor monotherapy for acute coronary syndrome using individual patient data from the TICO and T-PASS trials</dc:title>
<dc:identifier>pmid:39422377</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae685</dc:identifier>
</item>
<item>
<title>Overdrive pacing for ventricular fibrillation storm after myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39422362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 18:ehae698. doi: 10.1093/eurheartj/ehae698. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39422362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39422362</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae698>10.1093/eurheartj/ehae698</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39422362</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jan Charton</dc:creator>
<dc:creator>Xavier Bouteiller</dc:creator>
<dc:creator>Estelle Gandjbakhch</dc:creator>
<dc:creator>Xavier Waintraub</dc:creator>
<dc:creator>Cedric Klein</dc:creator>
<dc:creator>Philippe Maury</dc:creator>
<dc:creator>Pierre Baudinaud</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Romain Tixier</dc:creator>
<dc:creator>Thomas Baudinet</dc:creator>
<dc:creator>Frederic Sacher</dc:creator>
<dc:creator>Mélèze Hocini</dc:creator>
<dc:creator>Michel Haïssaguerre</dc:creator>
<dc:creator>Josselin Duchateau</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Overdrive pacing for ventricular fibrillation storm after myocardial infarction</dc:title>
<dc:identifier>pmid:39422362</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae698</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Do older patients with non-ST-segment elevation myocardial infarction receive any benefit from a routine invasive strategy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39422263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 18:ehae684. doi: 10.1093/eurheartj/ehae684. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39422263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39422263</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae684>10.1093/eurheartj/ehae684</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39422263</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Do older patients with non-ST-segment elevation myocardial infarction receive any benefit from a routine invasive strategy?</dc:title>
<dc:identifier>pmid:39422263</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae684</dc:identifier>
</item>
<item>
<title>Subgroup effects of ticagrelor treatment strategies: credibility considerations in an individual patient data meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39422250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 18:ehae683. doi: 10.1093/eurheartj/ehae683. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39422250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39422250</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae683>10.1093/eurheartj/ehae683</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39422250</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Tengfei Li</dc:creator>
<dc:creator>Jinhui Tian</dc:creator>
<dc:creator>Li Zhou</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Subgroup effects of ticagrelor treatment strategies: credibility considerations in an individual patient data meta-analysis</dc:title>
<dc:identifier>pmid:39422250</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae683</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Using multiomic approaches to uncover multicellular immune programmes in coronary syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39422231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 18:ehae680. doi: 10.1093/eurheartj/ehae680. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39422231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39422231</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae680>10.1093/eurheartj/ehae680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39422231</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Using multiomic approaches to uncover multicellular immune programmes in coronary syndromes</dc:title>
<dc:identifier>pmid:39422231</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae680</dc:identifier>
</item>
<item>
<title>Latrophilin-2 Deletion in Cardiomyocyte Disrupts Cell Junction, Leading to D-CMP</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39421931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Lphn2 is a critical regulator of heart integrity by controlling mitochondrial functions and cell-to-cell junctions in cardiomyocytes. Its deficiency leads to D-CMP, which can be rescued by activators of the p38-MAPK pathway.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 18. doi: 10.1161/CIRCRESAHA.124.324670. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Latrophilin-2 (Lphn2), an adhesive GPCR (G protein-coupled receptor), was found to be a specific marker of cardiac progenitors during the differentiation of pluripotent stem cells into cardiomyocytes or during embryonic heart development in our previous studies. Its role in adult heart physiology, however, remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The embryonic lethality resulting from <i>Lphn2</i> deletion necessitates the establishment of cardiomyocyte-specific, tamoxifen-inducible <i>Lphn2</i> knockout mice, which was achieved by crossing <i>Lphn2</i><sup>flox/flox</sup> mice with mice having MerCreMer (tamoxifen-inducible Cre recombinase) under the α-myosin heavy chain promoter.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Tamoxifen treatment for several days completely suppressed Lphn2 expression, specifically in the myocardium, and induced the dilated cardiomyopathy (D-CMP) phenotype with serious arrhythmia and sudden death in a short period of time. Transmission electron microscopy showed mitochondrial abnormalities, blurred Z-discs, and dehiscent myofibrils. The D-CMP phenotype, or heart failure, worsened during myocardial infarction. In a mechanistic study of D-CMP, <i>Lphn2</i> knockout suppressed PGC-1α and mitochondrial dysfunction, leading to the accumulation of reactive oxygen species and the global suppression of junctional molecules, such as N-cadherin (adherens junction), DSC-2 (desmocollin-2; desmosome), and connexin-43 (gap junction), leading to the dehiscence of cardiac myofibers and serious arrhythmia. In an experimental therapeutic trial, activators of p38-MAPK, which is a downstream signaling molecule of Lphn2, remarkably rescued the D-CMP phenotype of <i>Lphn2</i> knockout in the heart by restoring PGC-1α and mitochondrial function and recovering global junctional proteins.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Lphn2 is a critical regulator of heart integrity by controlling mitochondrial functions and cell-to-cell junctions in cardiomyocytes. Its deficiency leads to D-CMP, which can be rescued by activators of the p38-MAPK pathway.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39421931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39421931</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324670>10.1161/CIRCRESAHA.124.324670</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39421931</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Minjun Kang</dc:creator>
<dc:creator>Choon-Soo Lee</dc:creator>
<dc:creator>HyunJu Son</dc:creator>
<dc:creator>Jeongha Lee</dc:creator>
<dc:creator>Jaewon Lee</dc:creator>
<dc:creator>Hyun Ju Seo</dc:creator>
<dc:creator>Moo-Kang Kim</dc:creator>
<dc:creator>Murim Choi</dc:creator>
<dc:creator>Hyun-Jai Cho</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Latrophilin-2 Deletion in Cardiomyocyte Disrupts Cell Junction, Leading to D-CMP</dc:title>
<dc:identifier>pmid:39421931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324670</dc:identifier>
</item>
<item>
<title>Shear-Sensing by C-Reactive Protein: Linking Aortic Stenosis and Inflammation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39421928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We identify a novel mechanism of shear-induced pCRP dissociation, which results in the activation of cells central to the development of AS. This novel mechanosensing mechanism of pCRP dissociation to mCRP is likely also relevant to other pathologies involving increased shear rates, such as in atherosclerotic and injured arteries.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 18. doi: 10.1161/CIRCRESAHA.124.324248. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: CRP (C-reactive protein) is a prototypical acute phase reactant. Upon dissociation of the pentameric isoform (pCRP [pentameric CRP]) into its monomeric subunits (mCRP [monomeric CRP]), it exhibits prothrombotic and proinflammatory activity. Pathophysiological shear rates as observed in aortic valve stenosis (AS) can influence protein conformation and function as observed with vWF (von Willebrand factor). Given the proinflammatory function of dissociated CRP and the important role of inflammation in the pathogenesis of AS, we investigated whether shear stress can modify CRP conformation and induce inflammatory effects relevant to AS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To determine the effects of pathological shear rates on the function of human CRP, pCRP was subjected to pathophysiologically relevant shear rates and analyzed using biophysical and biochemical methods. To investigate the effect of shear on CRP conformation in vivo, we used a mouse model of arterial stenosis. Levels of mCRP and pCRP were measured in patients with severe AS pre- and post-transcatheter aortic valve implantation, and the presence of CRP was investigated on excised valves from patients undergoing aortic valve replacement surgery for severe AS. Microfluidic models of AS were then used to recapitulate the shear rates of patients with AS and to investigate this shear-dependent dissociation of pCRP and its inflammatory function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Exposed to high shear rates, pCRP dissociates into its proinflammatory monomers (mCRP) and aggregates into large particles. Our in vitro findings were further confirmed in a mouse carotid artery stenosis model, where the administration of human pCRP led to the deposition of mCRP poststenosis. Patients undergoing transcatheter aortic valve implantation demonstrated significantly higher mCRP bound to circulating microvesicles pre-transcatheter aortic valve implantation compared with post-transcatheter aortic valve implantation. Excised human stenotic aortic valves display mCRP deposition. pCRP dissociated in a microfluidic model of AS and induces endothelial cell activation as measured by increased ICAM-1 and P-selectin expression. mCRP also induces platelet activation and TGF-β (transforming growth factor beta) expression on platelets.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We identify a novel mechanism of shear-induced pCRP dissociation, which results in the activation of cells central to the development of AS. This novel mechanosensing mechanism of pCRP dissociation to mCRP is likely also relevant to other pathologies involving increased shear rates, such as in atherosclerotic and injured arteries.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39421928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39421928</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324248>10.1161/CIRCRESAHA.124.324248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39421928</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Johannes Zeller</dc:creator>
<dc:creator>Julia Loseff-Silver</dc:creator>
<dc:creator>Khashayar Khoshmanesh</dc:creator>
<dc:creator>Sara Baratchi</dc:creator>
<dc:creator>Austin Lai</dc:creator>
<dc:creator>Tracy L Nero</dc:creator>
<dc:creator>Abhishek Roy</dc:creator>
<dc:creator>Anna Watson</dc:creator>
<dc:creator>Nalin Dayawansa</dc:creator>
<dc:creator>Prerna Sharma</dc:creator>
<dc:creator>Anastasia Barbaro-Wahl</dc:creator>
<dc:creator>Yung Chih Chen</dc:creator>
<dc:creator>Mitchell Moon</dc:creator>
<dc:creator>Mark Louis P Vidallon</dc:creator>
<dc:creator>Angela Huang</dc:creator>
<dc:creator>Julia Thome</dc:creator>
<dc:creator>Karen S Cheung Tung Shing</dc:creator>
<dc:creator>Dalton Harvie</dc:creator>
<dc:creator>Marie N Bongiovanni</dc:creator>
<dc:creator>David Braig</dc:creator>
<dc:creator>Craig J Morton</dc:creator>
<dc:creator>Nay M Htun</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>Anthony Walton</dc:creator>
<dc:creator>John Horowitz</dc:creator>
<dc:creator>Xiaowei Wang</dc:creator>
<dc:creator>Geoffrey Pietersz</dc:creator>
<dc:creator>Michael W Parker</dc:creator>
<dc:creator>Steffen U Eisenhardt</dc:creator>
<dc:creator>James D McFadyen</dc:creator>
<dc:creator>Karlheinz Peter</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Shear-Sensing by C-Reactive Protein: Linking Aortic Stenosis and Inflammation</dc:title>
<dc:identifier>pmid:39421928</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324248</dc:identifier>
</item>
<item>
<title>Ferroptosis Mediated Inflammation Promotes Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39421926/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Ferroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 18. doi: 10.1161/CIRCRESAHA.123.324138. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species generation, results in lipid peroxidation and ferroptosis. Ferroptosis is an inflammatory mode of cell death that promotes complement activation and macrophage recruitment. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit cellular phenotypes that promote ferroptosis. Moreover, there is ectopic complement deposition and inflammatory macrophage accumulation in the pulmonary vasculature. However, the effects of ferroptosis inhibition on these pathogenic mechanisms and the cellular landscape of the pulmonary vasculature are incompletely defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Multiomics and physiological analyses evaluated how ferroptosis inhibition-modulated preclinical PAH. The impact of adeno-associated virus 1-mediated expression of the proferroptotic protein ACSL (acyl-CoA synthetase long-chain family member) 4 on PAH was determined, and a genetic association study in humans further probed the relationship between ferroptosis and pulmonary hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Ferrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity in monocrotaline rats. RNA-sequencing and proteomics analyses demonstrated that ferroptosis was associated with PAH severity. RNA-sequencing, proteomics, and confocal microscopy revealed that complement activation and proinflammatory cytokines/chemokines were suppressed by ferrostatin-1. In addition, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundance and gene activation patterns as revealed by deconvolution RNA-sequencing. Ferroptotic pulmonary arterial endothelial cell damage-associated molecular patterns restructured the transcriptomic signature and mitochondrial morphology, promoted the proliferation of pulmonary artery smooth muscle cells, and created a proinflammatory phenotype in monocytes in vitro. Adeno-associated virus 1-<i>Acsl4</i> induced an inflammatory PAH phenotype in rats. Finally, single-nucleotide polymorphisms in 6 ferroptosis genes identified a potential link between ferroptosis and pulmonary hypertension severity in the Vanderbilt BioVU repository.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Ferroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39421926/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39421926</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324138>10.1161/CIRCRESAHA.123.324138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39421926</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Felipe Kazmirczak</dc:creator>
<dc:creator>Neal T Vogel</dc:creator>
<dc:creator>Sasha Z Prisco</dc:creator>
<dc:creator>Michael T Patterson</dc:creator>
<dc:creator>Jeffrey Annis</dc:creator>
<dc:creator>Ryan T Moon</dc:creator>
<dc:creator>Lynn M Hartweck</dc:creator>
<dc:creator>Jenna B Mendelson</dc:creator>
<dc:creator>Minwoo Kim</dc:creator>
<dc:creator>Natalia Calixto Mancipe</dc:creator>
<dc:creator>Todd Markowski</dc:creator>
<dc:creator>LeAnn Higgins</dc:creator>
<dc:creator>Candace Guerrero</dc:creator>
<dc:creator>Ben Kremer</dc:creator>
<dc:creator>Madelyn L Blake</dc:creator>
<dc:creator>Christopher J Rhodes</dc:creator>
<dc:creator>Jesse W Williams</dc:creator>
<dc:creator>Evan L Brittain</dc:creator>
<dc:creator>Kurt W Prins</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Ferroptosis Mediated Inflammation Promotes Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:39421926</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324138</dc:identifier>
</item>
<item>
<title>EPHB4-RASA1 Inhibition of PIEZO1 Ras Activation Drives Lymphatic Valvulogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39421925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: EPHB4 is necessary for LV valve specification, continued valve development postspecification, and valve maintenance. LV valve specification requires physical interaction between EPHB4 and RASA1 to limit activation of the Ras-MAPK pathway in lymphatic endothelial cells. Specifically, EPHB4-RASA1 physical interaction is necessary to dampen Ras-MAPK activation induced through the PIEZO1 oscillatory shear stress sensor. These findings reveal the mechanism by which EPHB4 and RASA1...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 18. doi: 10.1161/CIRCRESAHA.124.325383. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: EPHB4 (ephrin receptor B4) and the RASA1 (p120 Ras GTPase-activating protein) are necessary for the development of lymphatic vessel (LV) valves. However, precisely how EPHB4 and RASA1 regulate LV valve development is unknown. In this study, we examine the mechanisms by which EPHB4 and RASA1 regulate the development of LV valves.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used LV-specific inducible EPHB4-deficient mice and EPHB4 knockin mice that express a form of EPHB4 that is unable to bind RASA1 yet retains protein tyrosine kinase activity (EPHB4 2YP) to study the role of EPHB4 and RASA1 in LV valve development in the embryo and LV valve maintenance in adults. We also used human dermal lymphatic endothelial cells in vitro to study the role of EPHB4 and RASA1 as regulators of LV valve specification induced by oscillatory shear stress, considered the trigger for LV valve specification in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: LV valve specification, continued valve development postspecification, and LV valve maintenance were blocked upon induced loss of EPHB4 in LV. LV specification and maintenance were also impaired in EPHB4 2YP mice. Defects in LV development were reversed by inhibition of the Ras-MAPK (mitogen-activated protein kinase) signaling pathway. In human dermal lymphatic endothelial cells, loss of expression of EPHB4 or its ephrin b2 ligand, loss of expression of RASA1, and inhibition of physical interaction between EPHB4 and RASA1 resulted in dysregulated oscillatory shear stress-induced Ras-MAPK activation and impaired expression of LV specification markers that could be rescued by Ras-MAPK pathway inhibition. The same results were observed when human dermal lymphatic endothelial cells were stimulated with the Yoda1 agonist of the PIEZO1 oscillatory shear stress sensor. Although Yoda1 increased the number of LV valves when administered to wild-type embryos, it did not increase LV valve number when administered to EPHB4 2YP embryos.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: EPHB4 is necessary for LV valve specification, continued valve development postspecification, and valve maintenance. LV valve specification requires physical interaction between EPHB4 and RASA1 to limit activation of the Ras-MAPK pathway in lymphatic endothelial cells. Specifically, EPHB4-RASA1 physical interaction is necessary to dampen Ras-MAPK activation induced through the PIEZO1 oscillatory shear stress sensor. These findings reveal the mechanism by which EPHB4 and RASA1 regulate the development of LV valves.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39421925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39421925</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325383>10.1161/CIRCRESAHA.124.325383</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39421925</guid>
<pubDate>Fri, 18 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Di Chen</dc:creator>
<dc:creator>Yipei Tang</dc:creator>
<dc:creator>Philip E Lapinski</dc:creator>
<dc:creator>David Wiggins</dc:creator>
<dc:creator>Eva M Sevick</dc:creator>
<dc:creator>Michael J Davis</dc:creator>
<dc:creator>Philip D King</dc:creator>
<dc:date>2024-10-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>EPHB4-RASA1 Inhibition of PIEZO1 Ras Activation Drives Lymphatic Valvulogenesis</dc:title>
<dc:identifier>pmid:39421925</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325383</dc:identifier>
</item>
<item>
<title>IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39419025/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>Chemotherapy is often combined with immune checkpoint inhibitor (ICIs) to enhance immunotherapy responses. Despite the approval of chemo-immunotherapy in multiple human cancers, many immunologically cold tumors remain unresponsive. The mechanisms determining the immunogenicity of chemotherapy are elusive. Here, we identify the ER stress sensor IRE1α as a critical checkpoint that restricts the immunostimulatory effects of taxane chemotherapy and prevents the innate immune recognition of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 14:S0092-8674(24)01090-0. doi: 10.1016/j.cell.2024.09.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chemotherapy is often combined with immune checkpoint inhibitor (ICIs) to enhance immunotherapy responses. Despite the approval of chemo-immunotherapy in multiple human cancers, many immunologically cold tumors remain unresponsive. The mechanisms determining the immunogenicity of chemotherapy are elusive. Here, we identify the ER stress sensor IRE1α as a critical checkpoint that restricts the immunostimulatory effects of taxane chemotherapy and prevents the innate immune recognition of immunologically cold triple-negative breast cancer (TNBC). IRE1α RNase silences taxane-induced double-stranded RNA (dsRNA) through regulated IRE1-dependent decay (RIDD) to prevent NLRP3 inflammasome-dependent pyroptosis. Inhibition of IRE1α in Trp53<sup>-/-</sup> TNBC allows taxane to induce extensive dsRNAs that are sensed by ZBP1, which in turn activates NLRP3-GSDMD-mediated pyroptosis. Consequently, IRE1α RNase inhibitor plus taxane converts PD-L1-negative, ICI-unresponsive TNBC tumors into PD-L1<sup>high</sup> immunogenic tumors that are hyper-sensitive to ICI. We reveal IRE1α as a cancer cell defense mechanism that prevents taxane-induced danger signal accumulation and pyroptotic cell death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39419025/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39419025</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.032>10.1016/j.cell.2024.09.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39419025</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Longyong Xu</dc:creator>
<dc:creator>Fanglue Peng</dc:creator>
<dc:creator>Qin Luo</dc:creator>
<dc:creator>Yao Ding</dc:creator>
<dc:creator>Fei Yuan</dc:creator>
<dc:creator>Liting Zheng</dc:creator>
<dc:creator>Wei He</dc:creator>
<dc:creator>Sophie S Zhang</dc:creator>
<dc:creator>Xin Fu</dc:creator>
<dc:creator>Jin Liu</dc:creator>
<dc:creator>Ayse Sena Mutlu</dc:creator>
<dc:creator>Shuyue Wang</dc:creator>
<dc:creator>Ralf Bernd Nehring</dc:creator>
<dc:creator>Xingyu Li</dc:creator>
<dc:creator>Qianzi Tang</dc:creator>
<dc:creator>Catherine Li</dc:creator>
<dc:creator>Xiangdong Lv</dc:creator>
<dc:creator>Lacey E Dobrolecki</dc:creator>
<dc:creator>Weijie Zhang</dc:creator>
<dc:creator>Dong Han</dc:creator>
<dc:creator>Na Zhao</dc:creator>
<dc:creator>Eric Jaehnig</dc:creator>
<dc:creator>Jingyi Wang</dc:creator>
<dc:creator>Weiche Wu</dc:creator>
<dc:creator>Davis A Graham</dc:creator>
<dc:creator>Yumei Li</dc:creator>
<dc:creator>Rui Chen</dc:creator>
<dc:creator>Weiyi Peng</dc:creator>
<dc:creator>Yiwen Chen</dc:creator>
<dc:creator>Andre Catic</dc:creator>
<dc:creator>Zhibin Zhang</dc:creator>
<dc:creator>Bing Zhang</dc:creator>
<dc:creator>Anthony M Mustoe</dc:creator>
<dc:creator>Albert C Koong</dc:creator>
<dc:creator>George Miles</dc:creator>
<dc:creator>Michael T Lewis</dc:creator>
<dc:creator>Meng C Wang</dc:creator>
<dc:creator>Susan M Rosenberg</dc:creator>
<dc:creator>Bert W O'Malley</dc:creator>
<dc:creator>Thomas F Westbrook</dc:creator>
<dc:creator>Han Xu</dc:creator>
<dc:creator>Xiang H-F Zhang</dc:creator>
<dc:creator>C Kent Osborne</dc:creator>
<dc:creator>Jin Billy Li</dc:creator>
<dc:creator>Matthew J Ellis</dc:creator>
<dc:creator>Mothaffar F Rimawi</dc:creator>
<dc:creator>Jeffrey M Rosen</dc:creator>
<dc:creator>Xi Chen</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer</dc:title>
<dc:identifier>pmid:39419025</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.032</dc:identifier>
</item>
<item>
<title>Mineralocorticoid receptor antagonists for atrial fibrillation prevention: effective solution or empty promise?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39418065/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae687. doi: 10.1093/eurheartj/ehae687. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39418065/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39418065</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae687>10.1093/eurheartj/ehae687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39418065</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alireza Oraii</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>William F McIntyre</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mineralocorticoid receptor antagonists for atrial fibrillation prevention: effective solution or empty promise?</dc:title>
<dc:identifier>pmid:39418065</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae687</dc:identifier>
</item>
<item>
<title>What are the pros and cons of a nationwide abdominal aortic aneurysm screening programme?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39417718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae690. doi: 10.1093/eurheartj/ehae690. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39417718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39417718</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae690>10.1093/eurheartj/ehae690</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39417718</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roman Gottardi</dc:creator>
<dc:creator>Stoyan Kondov</dc:creator>
<dc:creator>Mario Lescan</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>What are the pros and cons of a nationwide abdominal aortic aneurysm screening programme?</dc:title>
<dc:identifier>pmid:39417718</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae690</dc:identifier>
</item>
<item>
<title>Utility of mineralocorticoid receptor antagonists in reducing burden of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39417714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae686. doi: 10.1093/eurheartj/ehae686. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39417714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39417714</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae686>10.1093/eurheartj/ehae686</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39417714</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Thalys Sampaio Rodrigues</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Han S Lim</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Utility of mineralocorticoid receptor antagonists in reducing burden of atrial fibrillation</dc:title>
<dc:identifier>pmid:39417714</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae686</dc:identifier>
</item>
<item>
<title>The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39417710/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>The increased sensitivity of novel DNA sequencing techniques has made it possible to identify somatic mutations in small circulating clones of haematopoietic stem cells. When the mutation affects a 'driver' gene, the mutant clone gains a competitive advantage and has the potential to expand over time, a phenomenon referred to as clonal haematopoiesis (CH), which is emerging as a new risk factor for various non-haematological conditions, most notably cardiovascular disease (e.g. heart failure)....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae682. doi: 10.1093/eurheartj/ehae682. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The increased sensitivity of novel DNA sequencing techniques has made it possible to identify somatic mutations in small circulating clones of haematopoietic stem cells. When the mutation affects a 'driver' gene, the mutant clone gains a competitive advantage and has the potential to expand over time, a phenomenon referred to as clonal haematopoiesis (CH), which is emerging as a new risk factor for various non-haematological conditions, most notably cardiovascular disease (e.g. heart failure). Dilated cardiomyopathy (DCM) is a form of non-ischaemic heart failure that is characterized by a heterogeneous aetiology. The first evidence is arising that CH plays an important role in the disease course in patients with DCM, and a strong association of CH with multiple aetiologies of DCM has been described (e.g. inflammation, chemotherapy, and atrial fibrillation). The myocardial inflammation induced by CH may be an important trigger for DCM development for an already susceptible heart, e.g. in the presence of genetic variants, environmental triggers, and comorbidities. Studies investigating the role of CH in the pathogenesis of DCM are expected to increase rapidly. To move the field forward, it will be important to report the methodology and results in a standardized manner, so results can be combined and compared. The accurate measurement of CH in patients with DCM can provide guidance of specific (anti-inflammatory) therapies, as mutations in the CH driver genes prime the inflammasome pathway.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39417710/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39417710</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae682>10.1093/eurheartj/ehae682</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39417710</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Jose J Fuster</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:creator>Stephane R B Heymans</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy</dc:title>
<dc:identifier>pmid:39417710</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae682</dc:identifier>
</item>
<item>
<title>Beyond reproductive health: the cardiovascular risks of endometriosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39417705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae674. doi: 10.1093/eurheartj/ehae674. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39417705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39417705</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae674>10.1093/eurheartj/ehae674</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39417705</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Maria A Pabon</dc:creator>
<dc:creator>Xiaowen Wang</dc:creator>
<dc:creator>Kathryn M Rexrode</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Beyond reproductive health: the cardiovascular risks of endometriosis</dc:title>
<dc:identifier>pmid:39417705</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae674</dc:identifier>
</item>
<item>
<title>The International Cardiomyopathy Network: a manifesto for change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39417204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae692. doi: 10.1093/eurheartj/ehae692. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39417204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39417204</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae692>10.1093/eurheartj/ehae692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39417204</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Perry M Elliott</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The International Cardiomyopathy Network: a manifesto for change</dc:title>
<dc:identifier>pmid:39417204</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae692</dc:identifier>
</item>
<item>
<title>Retraction notice to Gedatolisib Associated Acute Myocarditis in a Patient With Breast Adenocarcinoma: J Am Coll Cardiol. 2024;83(13 Suppl):3575</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39415403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>The abstract "Gedatolisib Associated Acute Myocarditis in a Patient with Breast Adenocarcinoma" has been retracted at the request of the Editor-in-Chief because it was published before the completion of the clinical trial and full analysis of all data. There are no concerns about the findings as reported. This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22;84(17):1683. doi: 10.1016/j.jacc.2024.09.017.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The abstract "Gedatolisib Associated Acute Myocarditis in a Patient with Breast Adenocarcinoma" has been retracted at the request of the Editor-in-Chief because it was published before the completion of the clinical trial and full analysis of all data. There are no concerns about the findings as reported. This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39415403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39415403</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.017>10.1016/j.jacc.2024.09.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39415403</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Miles Shen</dc:creator>
<dc:creator>Mohamad Khattab</dc:creator>
<dc:creator>Emmanuel Akintoye</dc:creator>
<dc:creator>Lauren Anne Baldassarre</dc:creator>
<dc:creator>Jennifer Kwan</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Retraction notice to Gedatolisib Associated Acute Myocarditis in a Patient With Breast Adenocarcinoma: J Am Coll Cardiol. 2024;83(13 Suppl):3575</dc:title>
<dc:identifier>pmid:39415403</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.017</dc:identifier>
</item>
<item>
<title>Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39415402/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>Obesity is an ongoing pandemic and is associated with the development of heart failure (HF), and especially HF with preserved ejection fraction. The definition of obesity is currently based on anthropometric measurements but neglects the location and molecular properties of excess fat. Important depots associated with HF development are subcutaneous adipose tissue and visceral adipose tissue, both located in the abdominal region, and epicardial adipose tissue (EAT) surrounding the myocardium....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22;84(17):1666-1677. doi: 10.1016/j.jacc.2024.07.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Obesity is an ongoing pandemic and is associated with the development of heart failure (HF), and especially HF with preserved ejection fraction. The definition of obesity is currently based on anthropometric measurements but neglects the location and molecular properties of excess fat. Important depots associated with HF development are subcutaneous adipose tissue and visceral adipose tissue, both located in the abdominal region, and epicardial adipose tissue (EAT) surrounding the myocardium. However, mechanisms linking these different adipose tissue depots to HF development are incompletely understood. EAT in particular is of great interest because of its close proximity to the heart. In this review, we therefore focus on the characteristics of different adipose tissue depots and their response to obesity. In addition, we evaluate how different mechanisms associated with EAT expansion potentially contribute to HF and in particular HF with preserved ejection fraction development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39415402/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39415402</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.016>10.1016/j.jacc.2024.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39415402</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Just Dronkers</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Laura M G Meems</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue</dc:title>
<dc:identifier>pmid:39415402</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.016</dc:identifier>
</item>
<item>
<title>Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39413786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>Cardiac fibrosis impairs cardiac function, but no effective clinical therapies exist. To address this unmet need, we employed a high-throughput screening for antifibrotic compounds using human induced pluripotent stem cell (iPSC)-derived cardiac fibroblasts (CFs). Counter-screening of the initial candidates using iPSC-derived cardiomyocytes and iPSC-derived endothelial cells excluded hits with cardiotoxicity. This screening process identified artesunate as the lead compound. Following...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 12:S0092-8674(24)01092-4. doi: 10.1016/j.cell.2024.09.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac fibrosis impairs cardiac function, but no effective clinical therapies exist. To address this unmet need, we employed a high-throughput screening for antifibrotic compounds using human induced pluripotent stem cell (iPSC)-derived cardiac fibroblasts (CFs). Counter-screening of the initial candidates using iPSC-derived cardiomyocytes and iPSC-derived endothelial cells excluded hits with cardiotoxicity. This screening process identified artesunate as the lead compound. Following profibrotic stimuli, artesunate inhibited proliferation, migration, and contraction in human primary CFs, reduced collagen deposition, and improved contractile function in 3D-engineered heart tissues. Artesunate also attenuated cardiac fibrosis and improved cardiac function in heart failure mouse models. Mechanistically, artesunate targeted myeloid differentiation factor 2 (MD2) and inhibited MD2/Toll-like receptor 4 (TLR4) signaling pathway, alleviating fibrotic gene expression in CFs. Our study leverages multiscale drug screening that integrates a human iPSC platform, tissue engineering, animal models, in silico simulations, and multiomics to identify MD2 as a therapeutic target for cardiac fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39413786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39413786</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.034>10.1016/j.cell.2024.09.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39413786</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Hao Zhang</dc:creator>
<dc:creator>Phung N Thai</dc:creator>
<dc:creator>Rabindra V Shivnaraine</dc:creator>
<dc:creator>Lu Ren</dc:creator>
<dc:creator>Xuekun Wu</dc:creator>
<dc:creator>Dirk H Siepe</dc:creator>
<dc:creator>Yu Liu</dc:creator>
<dc:creator>Chengyi Tu</dc:creator>
<dc:creator>Hye Sook Shin</dc:creator>
<dc:creator>Arianne Caudal</dc:creator>
<dc:creator>Souhrid Mukherjee</dc:creator>
<dc:creator>Jeremy Leitz</dc:creator>
<dc:creator>Wilson Tan Lek Wen</dc:creator>
<dc:creator>Wenqiang Liu</dc:creator>
<dc:creator>Wenjuan Zhu</dc:creator>
<dc:creator>Nipavan Chiamvimonvat</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target</dc:title>
<dc:identifier>pmid:39413786</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.034</dc:identifier>
</item>
<item>
<title>Parsing Signal vs Noise-Secondary Analyses of RCTs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412815/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3329. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412815/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39412815</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3329>10.1001/jamacardio.2024.3329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412815</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Parsing Signal vs Noise-Secondary Analyses of RCTs</dc:title>
<dc:identifier>pmid:39412815</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3329</dc:identifier>
</item>
<item>
<title>Aortic Stenosis, Heart Failure, and Aortic Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412797/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241019100901&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: HF development in AS is multifactorial and its link to left ventricular dysfunction is a complex process. Delineating the determinants of HF admissions in AS is crucial for identifying individuals at high risk. Identifying the early signs of left ventricular decompensation by using surrogate markers may be the key, even before left ventricular function becomes impaired. Translating multimodality imaging techniques and biomarkers into routine clinical practice for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3486. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Heart failure (HF) and aortic stenosis (AS) frequently coexist, presenting a complex clinical challenge due to their intertwined pathophysiology and associated high morbidity and mortality. Despite numerous advancements in transcatheter and surgical aortic valve replacement (AVR), HF decompensation remains the leading cause of cardiac rehospitalization and a major predictor of mortality in patients with AS, before or after AVR. This review aims to provide a comprehensive analysis of the interplay between AS and HF, delving into myocardial changes caused by stenotic insult, the impact of AVR on these changes, and the prevalence and contributing elements of HF before and after AVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: The prevalence of HF remains high before and after AVR, particularly among patients with left ventricular dysfunction. Increased afterload from AS causes cardiac remodeling, which is initially benign but over time these changes become maladaptive, contributing to HF and increased mortality. The progression of HF is influenced by the degree of reverse cardiac remodeling, which can be affected by comorbid conditions, the hemodynamic performance of the valve prosthesis, and vascular stiffness. Several blood and imaging biomarkers offer insights into underlying AS pathophysiology, serving as mortality predictors and predicting HF in this patient population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: HF development in AS is multifactorial and its link to left ventricular dysfunction is a complex process. Delineating the determinants of HF admissions in AS is crucial for identifying individuals at high risk. Identifying the early signs of left ventricular decompensation by using surrogate markers may be the key, even before left ventricular function becomes impaired. Translating multimodality imaging techniques and biomarkers into routine clinical practice for evaluating cardiac damage and integrating these markers with patient and procedural factors that affect HF before and after AVR can facilitate timely intervention, minimizing the likelihood of HF progression and influencing future guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412797/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241019100901&v=2.18.0.post9+e462414">39412797</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3486>10.1001/jamacardio.2024.3486</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412797</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Siddhartha Mengi</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Marisa Avvedimento</dc:creator>
<dc:creator>Attilio Galhardo</dc:creator>
<dc:creator>Mathieu Bernier</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aortic Stenosis, Heart Failure, and Aortic Valve Replacement</dc:title>
<dc:identifier>pmid:39412797</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3486</dc:identifier>
</item>





























</channel>
</rss>